{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:26Z","timestamp":1791976106666,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T23:29:42Z","timestamp":1744759782000},"page":"603-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project"],"prefix":"10.1016","volume":"8","author":[{"given":"Alexandra","family":"Masson-Lecomte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Grisay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien Van","family":"Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry N.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Haese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Govaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Litiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.03.005_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.005_b0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.005_b0015","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.005_b0020","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.03.005_b0025","doi-asserted-by":"crossref","unstructured":"Geynisman DM, Abbosh PH, Ross E, et al. Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1). J Clin Oncol. In press. https:\/\/doi.org\/10.1200\/jco-24-01214.","DOI":"10.1200\/JCO-24-01214"},{"key":"10.1016\/j.euo.2025.03.005_b0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.euf.2019.08.009","article-title":"Clinical complete response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a call for standardized assessments and definitions","volume":"6","author":"Winoker","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.03.005_b0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.005_b0040","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.juro.2009.01.115","article-title":"A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)","volume":"181","author":"deVere White","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.005_b0045","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233020","article-title":"Neoadjuvant chemotherapy VI-RADS scores for assessing muscle-invasive bladder cancer response to neoadjuvant immunotherapy with multiparametric MRI","volume":"313","author":"Brembilla","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2025.03.005_b0050","doi-asserted-by":"crossref","unstructured":"Dehghanpour A, Pecoraro M, Messina E, et al. Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study. Eur Radiol. In press. https:\/\/doi.org\/10.1007\/s00330-024-11327-w.","DOI":"10.1007\/s00330-024-11327-w"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:55:36Z","timestamp":1748436936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112500080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S258893112500080X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}